Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404]
1 Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. Electronic address: [email protected].
2 Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, via Manzoni 56, Rozzano, Milan 20089, Italy; Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
3 Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O. Clinical di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
4 Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
5 Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom.
6 Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.